Xarelto, the popular blood thinner that has triggered roughly 25,000 lawsuits, has once again hit the news headlines. Recently, Bayer and Janssen Pharmaceuticals, a Johnson & Johnson division and the manufacturers and distributors of the drug, have agreed to settle a multi-district litigation suit for $775 million. The companies are not admitting fault but are calling the settlement a way to avoid spending more time and resources on litigation.
Background on Xarelto
After being FDA-approved in 2011 as a once-daily anticoagulant, Xarelto was used to reduce the likelihood of blood clots in patients with problems such as deep vein thrombosis and atrial fibrillation. It became so popular as an alternative to the long-term drug warfarin that it brought Bayer revenue of nearly $6 billion in a 24-month period. Bayer itself has noted that around 45 million patients have been given Xarelto by their medical providers.
Because of its blood thinning properties, Xarelto–generically known as rivaroxaban–sets patients up for potentially uncontrolled bleeding. Unlike other blood thinners, Xarelto had no antidote to combat bleeding, including gastrointestinal bleeding, until now. The drug AndrexXa can be used to reverse the extreme blood thinning effects of Xarelto and allow the blood to clot again.
About Xarelto Lawsuits
Individuals who took Xarelto began looking into product liability options several years ago after experiencing unexpected bleeding side effects. The side effects, such as internal bleeding, wound infection issues, strokes, and hemorrhages, were never included in the drug’s warning. Patients only discovered the issues with Xarelto after undergoing problems that required hospital stays, blood transfusions, and sky-high medical bills. No fewer than 370 patients died before their uncontrolled bleeding could be stopped.
Advocates for Xarelto victims were able to shed light on the fact that clinical trials for the drug may have been flawed. Though the FDA denies that this was an issue, legal professionals and medical experts still have doubt about whether Xarelto should have received FDA approval before undergoing other trials and studies.
Xarelto Settlement Realities
Settlement amounts for Xarelto lawsuits typically vary because some patients may have had more serious or deadly consequences than others. No doubt damages will be higher for families of the victims whose deaths are connected with Xarelto use. And some victims may opt out of a class action settlement so they can pursue other means of litigation against Bayer and Janssen Pharmaceuticals.
More victims of Xarelto may also want to talk to product liability lawyers if they took the drug and then experienced discolored urine, uncontrolled bleeding, bleeding gums not related to periodontal disease, red stools, stroke, bleeding event, heavier than normal menstruation, coughing up blood clots, or vomiting blood.
Philadelphia Product Liability Lawyers at McCann Dillon Jaffe & Lamb, LLC Strive to Hold Pharmaceutical Manufacturers Accountable
If you or a loved one has been harmed by a dangerous or defective drug, you may be entitled to compensation. Call McCann Dillon Jaffe & Lamb, LLC to get advice from a Philadelphia product liability lawyer today. Call 215-569-8488 or complete an online contact form to schedule a free initial consultation. From our offices in Philadelphia and Haddonfield, New Jersey, we serve clients across southeastern Pennsylvania, including Chester County and Delaware County. We also have offices in Wilmington to assist clients throughout Delaware.